Latest News on LLY

Financial News Based On Company


Advertisement
Advertisement

Will the first approved psychedelic become a blockbuster?

https://www.pharmavoice.com/news/race-first-psilocybin-blockbuster-compass-usona/875270/
The race to gain FDA approval for a psychedelic treatment is intensifying between Compass Pathways and Usona Institute. While Compass's psilocybin-based candidate for treatment-resistant depression, COMP360, is widely predicted to achieve blockbuster status, Usona's low-profile psilocybin drug for major depressive disorder recently surprised investors with reports of an earlier FDA filing. The commercial success of either drug will depend on factors like pricing, payer coverage, and patient access, with Compass navigating these dynamics while potentially paving the way for the broader psychedelic treatment market.

Rep. Michael A. Rulli Sells Off Shares of Lumentum Holdings Inc. (NASDAQ:LITE)

https://www.marketbeat.com/instant-alerts/congress-rep-michael-a-rulli-sells-off-shares-of-lumentum-holdings-inc-nasdaq-lite-2026-11-20/
Rep. Michael A. Rulli (Republican-Ohio) recently sold between $1,001 and $15,000 worth of Lumentum Holdings Inc. (NASDAQ:LITE) shares on November 4th, as disclosed in a November 18th filing. This transaction, executed from a Merrill Lynch Simple Managed Account, comes as Lumentum reported strong quarterly earnings, beating analyst estimates with significant revenue growth. Despite a "Moderate Buy" consensus rating from analysts, several firms have recently lowered their price targets for the stock.

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

https://www.pharmavoice.com/news/sanofi-regeneron-rare-disease-wins-lilly-dealmaking-dance/875276/
Sanofi and Regeneron have both achieved significant rare disease approvals, with Sanofi's Infilbray targeting neurological symptoms of type 3 Gaucher disease and Regeneron's Livsayis entering the generalized myasthenia gravis market. Meanwhile, Eli Lilly continues its aggressive dealmaking, announcing cancer research collaborations and acquisitions totaling billions, even as its popular GLP-1 weight loss drugs face increasing safety concerns and regulatory scrutiny. The article also touches on Moonshot AI's pivot towards scientific R&D, highlighting the growing intersection of AI and biopharma despite governance challenges.

Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.17% on Nov 19: Facts Behind the Movement

https://www.tradingkey.com/news/market-movers/262313883-market-movers-vrtx-20261119
Vertex Pharmaceuticals Inc. (VRTX) stock declined by 3.17% on November 19, primarily due to heightened pipeline scrutiny, commercialization challenges for new therapies like Casgevy, and broader sector-wide investor repositioning. Despite a strong cystic fibrosis franchise, investor sentiment is increasingly influenced by the slow ramp-up of non-CF growth drivers and competitive pressures. Technical indicators show a neutral MACD and RSI but an oversold Williams %R, while analysts maintain an average price target of $590.66.

Sonesitatug vedotin granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers

https://www.astrazeneca.com/media-centre/press-releases/2026/sonesitatug-vedotin-granted-priority-review-us-for-2nd-later-line-treatment-patients-with-cldn182-positive-advanced-gastric-gej-cancers.html
AstraZeneca's Biologics License Application for sonesitatug vedotin (Sone-Ve) has been granted Priority Review by the US FDA for the treatment of CLDN18.2-positive advanced gastric/GEJ cancers in 2nd and later-line settings. This decision is based on results from the CLARITY-Gastric01 Phase III trial, which demonstrated that Sone-Ve reduced the risk of death by 42% and significantly improved overall survival compared to standard care. The FDA's action date is anticipated in the second quarter of 2027, potentially offering a new targeted option for thousands of patients with limited treatment alternatives.
Advertisement

Colin Cieszynski’s Top Picks: Constellation Software, Eli Lilly & Hasbro

https://www.bnnbloomberg.ca/video/shows/market-call/2026/11/19/colin-cieszynskis-top-picks-constellation-software-eli-lilly-hasbro/
Colin Cieszynski, portfolio manager and chief market strategist at SIA Wealth Management, has shared his top stock picks. His selections include Constellation Software, Eli Lilly, and Hasbro. The picks were announced on November 19, 2026, at 1:10 p.m. EST.

PFE Inks $2.6B Licensing Deal With Chinese Biotech for CAR-T Therapies

https://www.tradingview.com/news/zacks:1561f48db094b:0-pfe-inks-2-6b-licensing-deal-with-chinese-biotech-for-car-t-therapies/
Pfizer (PFE) has signed a $2.6 billion exclusive licensing deal with China's Starna Therapeutics for three investigational CAR-T programs targeting autoimmune diseases. This deal gives Pfizer rights outside Greater China to develop, manufacture, and commercialize these preclinical in vivo CAR-T therapies, with an upfront payment of $330 million and up to $2.3 billion in milestone payments. This move aligns with Pfizer's strategy to explore next-generation CAR-T therapies that modify T cells directly inside the patient's body, reducing complexities and costs associated with traditional CAR-T treatments.

BAC: SEC Form FWP filed by Bank of America Corporation

https://www.quantisnow.com/insight/sec-form-fwp-filed-by-bank-of-america-corporation-6800350
BofA Finance LLC, guaranteed by Bank of America Corporation, has filed an SEC Form FWP regarding new market-linked notes due December 3, 2029. These notes offer a contingent coupon of at least 17.00% per year, with payments tied to the performance of Blackstone, Eli Lilly, and Target stocks. Investors face potential principal loss if the underlying stocks fall below a 60% threshold at maturity.

Merck & Co Inc Stock (MRK) Moved Down by 3.02% on Nov 19: Key Drivers Unveiled

https://www.tradingkey.com/news/market-movers/262313616-market-movers-mrk-20261119
Merck & Co Inc (MRK) stock fell by 3.02% on November 19, driven by concerns over its pipeline execution, Keytruda patent expiry, and volatility in Gardasil sales, particularly in China. The company also faces broader industry headwinds from regulatory scrutiny on drug pricing. Technical analysis indicates a MACD sell signal and an oversold Williams %R, while fundamental support exists from strong cash flow and dividends, with future performance dependent on clinical milestones and pipeline diversification.

PRISM MarketView Highlights Four Small Caps Working on Alzheimer’s...

https://www.quantisnow.com/insight/prism-marketview-highlights-four-small-caps-working-on-alzheimers-disease-6800341
PRISM MarketView published a feature on four small-cap companies—Annovis Bio (ANVS), AC Immune (ACIU), IGC Pharma (IGC), and Firefly Neuroscience (AIFF)—focusing on their progress in Alzheimer's disease research, timed with the CTAD 2026 conference. The article provides updates on each company's clinical trials, including expected timelines and key findings, emphasizing the promotional nature of the PRISM MarketView piece rather than new data disclosure. Shareholder-relevant information includes Annovis's continued Phase 3 trial, AC Immune's positive antibody responses, IGC Pharma's completed dosing, and Firefly's EEG system adoption.
Advertisement

3 ETFs That Hold AstraZeneca In Very Different Ways

https://simplywall.st/etfs/us/nysearca-ewu/news/3-etfs-that-hold-astrazeneca-in-very-different-ways
AstraZeneca's recent cancer treatment approval and high debt levels raise questions about its role in diversified portfolios. This article examines three ETFs—iShares MSCI United Kingdom ETF (EWU), Roundhill GLP-1 & Weight Loss ETF (OZEM), and JPMorgan Healthcare Leaders ETF (JDOC)—that hold AstraZeneca, each offering a different approach to balancing company-specific risks with broader market or sector exposure. Investors can choose between a broad UK market mix, a concentrated weight-loss drug focus, or a global healthcare industry spread.

Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled

https://investingnews.com/lexaria-s-human-study-glp-1-h26-7-completes-dosing-as-scheduled/
Lexaria Bioscience Corp. has completed the final dosing for its Human Pilot Study #7 (GLP-1-H26-7), which evaluates two oral DehydraTECH-semaglutide compositions against Novo's Wegovy® tablets over a five-week period. The study focused on safety, tolerability, and pharmacokinetic properties, including new DehydraTECH™ enhancements such as an oral tablet format and the incorporation of SNAC in both tablet and capsule forms for multi-dose evaluation. Lexaria will now proceed with laboratory analysis and data review before releasing further information.

Noninvasive MASH Diagnostic Tests Market Size and Growth Analysis Study 2026 to 2035

https://www.insightaceanalytic.com/report/noninvasive-mash-diagnostic-tests-market/3808
The global Noninvasive MASH Diagnostic Tests Market is projected to grow at a 16.0% CAGR from 2026 to 2035, driven by the increasing prevalence of MASH and the demand for less invasive diagnostic methods. North America is expected to lead this market due to its advanced healthcare infrastructure and high rates of metabolic disorders. Key market drivers include the push for early and accurate diagnosis, while challenges involve variability in diagnostic accuracy and standardization across testing methods.

As Sanofi's Pompe drug shortage drags on, some patients struggle to access treatments

https://www.cnbc.com/2026/11/19/as-pompe-drug-shortage-drags-on-patients-struggle-to-get-treatments.html
A shortage of Sanofi's Pompe disease drugs, Lumizyme and Nexviazyme, has continued for over three months due to manufacturing issues at its Ireland facility, leaving some patients unable to receive critical bi-weekly infusions. Patients fear that these interruptions could lead to irreversible health declines, with one patient likening the experience to a severe flu. The FDA has cited Sanofi for manufacturing violations unrelated to the Pompe drugs, which the company says has contributed to the supply disruption.

Valion Bio names former Army official and biotech CEO as advisor

https://www.streetinsider.com/Corporate+News/Valion+Bio+names+former+Army+official+and+biotech+CEO+as+advisor/27373151.html
Valion Bio, Inc. has appointed Armand Balboni, JD, MD, PhD, as an advisor to lead its scientific strategy and medical countermeasure development, particularly for its lead candidate, Entolimod. Dr. Balboni's extensive background includes serving as CEO of Appili Therapeutics Inc. and 24 years of military service with the U.S. Army, where he oversaw FDA-regulated clinical trials. His expertise will be crucial in advancing Entolimod, which has Fast Track and Orphan Drug designations, through government and strategic partnerships.
Advertisement

Merck signs Isomorphic Labs to design small-molecule drugs for a cancer target

https://mlq.ai/news/merck-signs-isomorphic-labs-to-design-small-molecule-drugs-for-a-cancer-target/
Merck has announced a research collaboration with Alphabet-backed Isomorphic Labs to discover small-molecule drug candidates for an unnamed oncology target. Isomorphic will use its IsoDDE engine and Merck's datasets to design molecules, with Merck handling development, manufacturing, and commercialization. Isomorphic will receive an upfront payment, milestones, and royalties, with an option to co-fund for higher royalties, though specific financial details were not disclosed.

Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies

https://www.pharmaceutical-technology.com/news/pfizer-inks-2-6bn-autoimmune-deal-with-chinas-starna-for-car-t-therapies/
Pfizer has signed a multi-billion-dollar licensing agreement with China's Starna Therapeutics for ex-China rights to three pre-IND in vivo CAR-T programmes targeting autoimmune diseases. The deal includes an upfront payment of $330m to Starna, with potential for an additional $2.3bn in development and commercial milestones, plus royalties. This move aligns with a broader industry trend towards in vivo CAR-T therapies, which are seen as more attractive due to reduced manufacturing complexities compared to ex vivo approaches.

Adagene doses first patient in phase 1 trial of ADG138

https://ca.investing.com/news/stock-market-news/adagene-doses-first-patient-in-phase-1-trial-of-adg138-93CH-4969381
Adagene Inc. (NASDAQ:ADAG) has announced that the first patient has been dosed in a phase 1 study for ADG138, a double-masked HER2×CD3 bispecific T-cell engager. The open-label study will assess the safety and preliminary efficacy of ADG138 in patients with HER2-positive advanced solid tumors, with dose escalation starting at 2 mg. Preclinical data for ADG138 showed reduced cytokine release, a longer apparent half-life, and tumor regression in various HER2 tumor models.

Biopharma Co. Targeting Alzheimer's Disease Process, Not Just Symptoms

https://www.streetwisereports.com/article/2026/11/18/biopharma-co-targeting-alzheimers-disease-process-not-just-symptoms.html
Cognition Therapeutics Inc. (CGTX) is developing an oral drug, zervimesine (CT1812), aimed at protecting brain cell connections from damage associated with Alzheimer's disease by preventing toxic amyloid-beta oligomers from binding to synapses. The company is presenting research on plasma p-tau217 screening in its Phase 2 START Alzheimer's trial, which is expected to yield topline results in H2 2027. Additionally, Cognition Therapeutics plans to initiate a Phase 3 program for dementia with Lewy body psychosis in mid-2027, following positive Phase 2 results.

RCS - Hutchmed China Ltd - China NMPA Approval of SYVIK

https://www.tradingview.com/news/reuters.com,2026-11-19:newsml_RSS8664Da:0-rcs-hutchmed-china-ltd-china-nmpa-approval-of-syvik/
HUTCHMED (China) Limited announced that China's NMPA has simultaneously approved two New Drug Applications for SYVIK® (sovleplenib) for the treatment of adult patients with chronic primary Immune Thrombocytopenia (ITP) and Warm Antibody Autoimmune Hemolytic Anemia (wAIHA). SYVIK® is the first novel Syk inhibitor approved in China, marking HUTCHMED's expansion into immunology beyond oncology. The approvals are supported by positive Phase III ESLIM-01 trial data for ITP and Phase II/III ESLIM-02 trial data for wAIHA, demonstrating significant efficacy and a tolerable safety profile.
Advertisement

Adagene doses first patient in phase 1 trial of ADG138

https://www.investing.com/news/company-news/adagene-doses-first-patient-in-phase-1-trial-of-adg138-93CH-5038605
Adagene Inc. (NASDAQ:ADAG) has announced that the first patient has been dosed in a phase 1 study for ADG138, a double-masked HER2×CD3 bispecific T-cell engager. The study will assess the safety and preliminary efficacy of ADG138 in patients with HER2-positive advanced solid tumors, with an aim to determine the recommended phase 2 dose. Preclinical data for ADG138 demonstrated reduced cytokine release, a longer half-life, and tumor regression in various HER2 tumor models.

Amgen Inc Stock (AMGN) Moved Down by 3.21% on Nov 18: What Signal Does It Send?

https://www.tradingkey.com/news/market-movers/262311625-market-movers-amgn-20261118
Amgen Inc. (AMGN) shares fell by 3.21% due to institutional caution regarding its clinical pipeline and challenges from patent cliffs and regulatory pricing pressures. Investors are closely watching the competitive dynamics of its investigational asset, MariTide, and the impact of the Inflation Reduction Act. Technical indicators show a neutral MACD and RSI, with an oversold Williams %R, while analysts maintain an average "Hold" rating with an average price target of $422.26.

Merck & Co Inc Stock (MRK) Moved Down by 3.35% on Nov 18: Facts Behind the Movement

https://www.tradingkey.com/news/market-movers/262311572-market-movers-mrk-20261118
Merck & Co Inc (MRK) stock declined by 3.35% due to operational challenges, sector rotation, and investor concerns over Keytruda's revenue concentration and impending patent cliff. The company also faces issues with its Gardasil vaccine franchise and risks from an aggressive M&A strategy. Despite a strong balance sheet, market participants are looking for proof of pipeline replacement power and stable organic growth beyond its primary assets.

Pfizer Pays $330 Million Upfront for Starna's In Vivo CAR-T Programs in $2.6 Billion Deal

https://finance.biggo.com/news/da621f80-59ef-40e7-ba51-06eb5c3a432b
Pfizer has agreed to an exclusive licensing deal with Starna Therapeutics, paying $330 million upfront for three pre-IND in vivo CAR-T programs targeting autoimmune diseases. The total deal value could reach $2.63 billion including milestones and royalties, giving Pfizer rights outside Greater China and an option for China rights, as well as access to Starna's technology for oncology and a separate research collaboration. This move places Pfizer in the emerging in vivo cell therapy field, which has seen increased dealmaking from other large drugmakers like Eli Lilly.

Pfizer leaps into ‘in vivo’ CAR-T with latest China deal

https://www.biopharmadive.com/news/pfizer-starna-in-vivo-cell-therapy-autoimmune-disease-deal/875018/
Pfizer has entered a significant collaboration with Starna Therapeutics, paying $330 million upfront and up to $2.3 billion in milestone payments, to develop "in vivo" cell therapies for autoimmune diseases. This deal marks Pfizer's entry into the competitive "in vivo" CAR-T research space, aiming to reprogram cells inside the body and potentially simplify current "ex vivo" CAR-T processes that require cell harvesting and modification outside the body. The partnership leverages Pfizer's RNA-based medicine expertise and highlights a growing trend among drugmakers to pursue "in vivo" therapies for conditions beyond cancer, including lupus and multiple sclerosis.
Advertisement

CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s

https://www.biospace.com/drug-development/ctad-2026-biogen-aribio-lead-the-way-in-slowing-cognitive-decline-in-alzheimers
At the 2026 Clinical Trials on Alzheimer’s Disease conference, Biogen and AriBio reported positive results for their Alzheimer's therapies. Biogen's anti-tau therapy, diranersen, showed a 38% slowing of clinical decline over two years, supporting its advancement to Phase 3. AriBio's PDE5 inhibitor, AR1001, achieved success in a Phase 3 trial by slowing clinical decline by 31% in a monotherapy subgroup, with plans to discuss results with the FDA.

Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026

https://www.manilatimes.net/2026/11/18/tmt-newswire/globenewswire/scribe-therapeutics-presents-new-data-advancing-the-potential-of-ultra-long-acting-genetic-medicines-for-cardiovascular-disease-at-aha-scientific-sessions-2026/2473091
Scribe Therapeutics presented new preclinical data at the American Heart Association (AHA) Scientific Sessions 2026 for its STX-1150 and STX-1200 programs, which aim to develop ultra-long-acting genetic medicines for cardiovascular disease. The data showed STX-1150 sustained over 50% LDL-C reduction for at least two years in non-human primates, while STX-1200 achieved over 95% Lp(a) reduction in non-human primates, reinforcing the potential for durable, single-treatment therapies. These programs are designed to address the unmet need for sustained lipid lowering and to translate the protective effects of natural human genetic variants into therapeutic interventions.

Teladoc Health Expands Comprehensive Weight Care Program with Employer Contribution Option for GLP-1 Medications

https://finance.yahoo.com/healthcare/articles/teladoc-health-expands-comprehensive-weight-133000556.html
Teladoc Health has expanded its Comprehensive Weight Care program to include an employer contribution option for FDA-approved GLP-1 medications, such as those from Eli Lilly and Company and Novo. This new offering aims to provide employers with greater flexibility in covering GLP-1 costs for their workforce while ensuring predictable spending. The program also integrates comprehensive clinical care, nutrition, and lifestyle support to achieve sustained health outcomes for employees and their families.

Insulin Delivery Devices Market to Reach US$ 43.11 Billion

https://www.openpr.com/news/4693095/insulin-delivery-devices-market-to-reach-us-43-11-billion
The global insulin delivery devices market is projected to grow from US$ 22.04 billion in 2025 to US$ 43.11 billion by 2033, exhibiting an 8.8% CAGR, driven by the increasing prevalence of diabetes and technological advancements. North America leads the market with a 43.50% share, while Asia-Pacific is expected to experience the fastest growth. Key players like Medtronic, Insulet Corporation, and Tandem Diabetes Care are innovating with smart pens, automated insulin delivery systems, and wearable devices to improve diabetes management.

FDA approves AstraZeneca's Klygefa, a once-weekly self-injected myasthenia gravis drug

https://mlq.ai/news/fda-approves-astrazenecas-klygefa-a-once-weekly-self-injected-myasthenia-gravis-drug/
The FDA has approved AstraZeneca's Klygefa (gefurulimab) for adults with generalized myasthenia gravis who are anti-AChR antibody positive. This once-weekly, self-administered subcutaneous autoinjector is the first dual-binding nanobody C5 inhibitor approved in the US. The approval was based on the PREVAIL Phase 3 trial, which demonstrated significant improvement in patient-reported daily living scores.
Advertisement

Teladoc Launches Employer Contribution Option for GLP-1s

https://medcitynews.com/2026/11/teladoc-launches-employer-contribution-option-for-glp-1s/
Teladoc Health has introduced a new offering that allows employers to contribute to the cost of GLP-1 medications for their employees, separate from traditional pharmacy benefits. This initiative aims to address the challenges employers face in covering GLP-1s for weight loss, providing a flexible contribution model with transparency and optional participant engagement requirements. The program also integrates guidance from obesity medicine clinicians, dietitians, and health coaches, emphasizing comprehensive support beyond just medication.

Alzheimer's Brain Scan Clinic Clears Major Medicare Hurdle

https://www.streetwisereports.com/article/2026/11/17/alzheimers-brain-scan-clinic-clears-major-medicare-hurdle.html
Grey Matters Health Inc. has achieved accreditation and completed Medicare and Medicaid enrollment for its flagship NovaScan Neuroimaging Clinics location in Davie, Florida. This allows the clinic to provide diagnostic PET imaging services for Alzheimer's and other neurodegenerative conditions to eligible patients. The company plans to establish a national network of 100-200 brain-specific PET imaging clinics across the U.S., utilizing its FDA-cleared CareMiBrain system.

Rythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR

https://www.tradingview.com/news/seekingalpha:772112785094b:0-rythm-pharmaceuticals-gains-on-report-eli-lilly-made-150-share-offer-with-cvr/
Rhythm Pharmaceuticals (RYTM) saw an 8% increase in its stock price following a report that Eli Lilly (LLY) is considering acquiring the company, along with Viking Therapeutics (VKTX), in the obesity market. This report comes after AstraZeneca (AZN) reportedly made a $124 per share offer for Rhythm last month. Eli Lilly's proposal is rumored to be around $150 per share with a contingent value right.

Lilly signs $5.9B cancer research deal with Cambridge company

https://www.bizjournals.com/boston/news/2026/11/17/eli-lilly-stipple-bio-deal.html
Eli Lilly has secured a collaboration worth up to $5.9 billion with Cambridge-based Stipple Bio for cancer research. The pharmaceutical giant is leveraging capital generated from its weight-loss drug sales to fund this significant deal. The agreement aims to advance cancer research efforts.

Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.26% on Nov 17: What Signal Does It Send?

https://www.tradingkey.com/news/market-movers/262309487-market-movers-bmy-20261117
Bristol-Myers Squibb Co (BMY) stock fell by 3.26% due to institutional profit-taking and concerns over the company's revenue transition, particularly the impending loss of exclusivity for key drugs like Eliquis and Opdivo. The market is scrutinizing the commercial success of newer assets to offset this generic erosion, alongside regulatory headwinds from Medicare drug price negotiations. Despite robust free cash flow and a defensive dividend yield, sustained multiple expansion depends on clear evidence of pipeline replacement power.
Advertisement

What NRx Pharmaceuticals (NRXP) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:490ac2592094b:0-what-nrx-pharmaceuticals-nrxp-said-on-its-q3-earnings-call/
NRx Pharmaceuticals reported higher Q3 patient revenue and a narrower net loss, outlining plans to commercialize its recently FDA-approved preservative-free ketamine product and advance experimental treatments for depression. The company also detailed its cash position, pipeline developments including a subcutaneous ketamine formulation and a DARPA-funded trial, and its HOPE Therapeutics clinics. NRx aims for profitability by 2027 and is pursuing early-stage programs for ALS and schizophrenia through its GeNeuro division.

Dr Reddy's v Boehringer Ingelheim: empagliflozin SPC falls for lack of plausibility

https://www.solicitorsjournal.com/sjarticle/dr-reddys-v-boehringer-ingelheim-empagliflozin-spc-falls-for-lack-of-plausibility?category=none
The Patents Court has invalidated Boehringer Ingelheim's basic patent for empagliflozin, the active ingredient in its diabetes drug Jardiance, due to a lack of plausibility that the compound would inhibit SGLT. This ruling also causes the supplementary protection certificate (SPC) to fall. However, a separate patent claiming a crystalline form of empagliflozin was upheld as valid.

Pfizer CEO: ‘China will be my major competition by 2030’

https://www.pharmaceutical-technology.com/news/pfizer-ceo-china-will-be-my-major-competition-by-2030/
Pfizer CEO Albert Bourla predicts that China will become Pfizer's main competitor by 2030, surpassing traditional Western big pharma companies. This forecast comes as China actively implements a five-year biomedical plan to boost its pharma exports and aims to develop 25% of global first-in-class drugs by the end of the decade. Bourla highlights China's rapid growth and cost-effectiveness in biotech, stressing the need for Pfizer to leverage AI to compete with this emerging powerhouse.

Biogen’s anti-tau Alzheimer’s drug benefits increase at 2 years

https://whtc.com/2026/11/17/biogens-anti-tau-alzheimers-drug-benefits-increase-at-2-years/
New trial data shows that Biogen's experimental anti-tau Alzheimer's drug, diranersen, slowed cognitive decline by 38% after two years in early Alzheimer's patients, an increase from 26% at 18 months. This lowest 60-milligram dose proved to be the most effective and well-tolerated, demonstrating the first instance of a tau-targeting drug slowing Alzheimer's progression. Biogen is now discussing Phase 3 trials with regulators and considering how diranersen could be used with other Alzheimer's treatments like Leqembi.

Pfizer CEO: ‘China will be my major competition by 2030’

https://www.pharmaceutical-technology.com/news/pfizer-ceo-china-will-be-my-major-competition-2030/
Pfizer CEO Albert Bourla predicts that China will become his company's primary competitor in the pharmaceutical industry by 2030, surpassing traditional Western big pharma. This forecast comes as China actively implements a five-year biomedical plan to boost its pharma exports and aims to develop 25% of global first-in-class drugs. Bourla emphasized the need for Pfizer to significantly increase speed and reduce costs, leveraging AI, to compete with China's growing biotech sector.
Advertisement

Biogen’s anti-tau Alzheimer’s drug benefits increase at 2 years

https://kelo.com/2026/11/17/biogens-anti-tau-alzheimers-drug-benefits-increase-at-2-years/
New trial data shows that Biogen's experimental anti-tau Alzheimer's drug, diranersen, significantly slowed cognitive decline in early Alzheimer's patients after two years. The lowest dose (60-milligram twice-yearly) improved cognitive decline by 38%, an increase from the 26% reported at 18 months, making it the first tau-targeting drug to demonstrate such efficacy. Biogen is now discussing Phase 3 trial outlines with regulators and exploring potential combination therapies with amyloid-targeting drugs like Leqembi.

Veru presents data on enobosarm for obesity treatment

https://www.investing.com/news/company-news/veru-presents-data-on-enobosarm-for-obesity-treatment-93CH-5033022
Veru Inc. presented new data from a post hoc analysis of its Phase 2b QUALITY study at ObesityWeek 2026, demonstrating that enobosarm 3mg combined with semaglutide helped elderly obese patients preserve lean muscle mass and improve physical function compared to semaglutide alone. Patients receiving enobosarm gained 0.3 kg of lean mass, while the placebo group lost 2.0 kg. The company is currently evaluating enobosarm in its Phase 2b PLATEAU clinical trial, with interim results expected in Q1 2027.

Karyopharm Announces FDA Acceptance of Supplemental New Drug Application for XPOVIO® (selinexor) Plus Ruxolitinib for the Treatment of Patients with Myelofibrosis

https://investors.karyopharm.com/2026-11-17-Karyopharm-Announces-FDA-Acceptance-of-Supplemental-New-Drug-Application-for-XPOVIO-R-selinexor-Plus-Ruxolitinib-for-the-Treatment-of-Patients-with-Myelofibrosis
Karyopharm Therapeutics Inc. announced that the FDA has accepted its supplemental New Drug Application (sNDA) for XPOVIO® (selinexor) in combination with ruxolitinib for patients with myelofibrosis, with a PDUFA target action date of June 28, 2027. This sNDA is based on positive results from the Phase 3 SENTRY trial. If approved, this combination could be the first approved combination therapy for myelofibrosis patients, addressing a significant unmet need.

Protagonist CEO Dinesh Patel Says ICOTYDE's 60,000 Prescriptions Mean No Equity Raise — and a $300 Million Buyback

https://finance.biggo.com/news/85ed3953d1fc2677
Protagonist Therapeutics CEO Dinesh Patel announced at the Jefferies Global Healthcare Conference that the company will not need an equity raise due to robust royalties from Johnson & Johnson's ICOTYDE psoriasis drug. The company plans a $300 million share buyback, indicating a shift in the biotech business model where value is captured at the point of partnership. Patel highlighted ICOTYDE's rapid launch with over 60,000 prescriptions and outlined Protagonist's pipeline, including an oral IL-17 inhibitor and an oral-only obesity portfolio, which are being funded by the successful partnership.

Berkshire Hathaway, Cisco And A Health Care Stock: CNBC’s ‘Final Trades’

https://www.benzinga.com/trading-ideas/long-ideas/26/11/63336317/berkshire-hathaway-cisco-and-a-health-care-stock-cnbcs-final-trades
CNBC's "Halftime Report Final Trades" featured picks including Berkshire Hathaway, Cisco Systems, and Eli Lilly. Jim Lebenthal recommended Berkshire Hathaway, citing a recent price target raise by UBS. Jenny Van Leeuwen Harrington highlighted Cisco's 5% free cash flow yield and strong Q1 earnings, while Joseph M. Terranova noted Eli Lilly's continued upward movement and recent acquisition of Calytrix Bio Inc.
Advertisement

Rhythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR (RYTM:NASDAQ)

https://seekingalpha.com/news/4673783-rythm-pharmaceuticals-gains-on-report-eli-lilly-made-150-share-offer-with-cvr
Rhythm Pharmaceuticals' stock increased by 8% following a report that Eli Lilly is considering acquiring two companies in the obesity market, one of which is Rhythm. This news comes after a separate report of AstraZeneca's bid for a competitor. The specific offer for Rhythm Pharmaceuticals is reported to be $150 per share with a CVR.

Cellectis plans 70% workforce cuts; Sanofi signs $1.2B DNA medicines deal; AstraZeneca buys Omniose

https://european-biotechnology.com/latest-news/cellectis-plans-70-workforce-cuts-sanofi-signs-1-2b-dna-medicines-deal-astrazeneca-buys-omniose/
Cellectis plans to cut up to 70% of its workforce between 2026 and 2027 to focus on in vivo gene editing treatments for severe hypertriglyceridemia and hypercholesterolemia. Meanwhile, Sanofi has signed a research collaboration and exclusive license agreement worth up to $1.2 billion with Seawolf for DNA-based medicines, and AstraZeneca has acquired Omniose to enhance its bacterial vaccine technology. Other news includes a proposed merger between Nuformix and Biovara, Biomatter raising $18 million for AI enzyme design, and Zealand seeking partners for rare-disease medicines to prioritize obesity treatments.

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

https://sg.finance.yahoo.com/news/invest-fidelity-msci-health-care-102003605.html
The Fidelity MSCI Health Care Index ETF (FHLC) offers diversified and low-cost exposure to the healthcare sector, making it an attractive option for long-term investors. With assets over $4.08 billion and an expense ratio of 0.08%, FHLC tracks the MSCI USA IMI Health Care Index. It currently holds a Zacks ETF Rank of 3 (Hold) and has shown a year-to-date gain of 21.32%.

Eli Lilly & Co (LLY) Receives a Buy from Barclays

https://www.theglobeandmail.com/investing/markets/stocks/LLY-N/pressreleases/8869880/eli-lilly-co-lly-receives-a-buy-from-barclays/
Barclays analyst Emily Field maintained a Buy rating on Eli Lilly & Co (LLY) with a price target of $1,550.00. This aligns with a general Strong Buy consensus among analysts, with an average price target of $1,520.14 for the company. Eli Lilly & Co recently reported strong quarterly revenues of $24.4 billion and a net profit of $6.45 billion for the quarter ending September 30.

Eli Lilly & Co (LLY) Receives a Buy from Barclays

https://www.theglobeandmail.com/investing/markets/stocks/LLY/pressreleases/8869880/eli-lilly-co-lly-receives-a-buy-from-barclays/
Barclays analyst Emily Field maintained a Buy rating on Eli Lilly & Co (LLY) and set a price target of $1,550.00. Field is noted as a 3-star analyst with a 2.5% average return. The general Street consensus for Eli Lilly & Co is a Strong Buy, with an average price target of $1,520.14.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement